Osteoporosis

Global Osteoporosis Drugs Market Research Report 2021-2025

Wed, 08 Sep 2021 15:45:00 +0000

Osteoporosis is a chronic disease in which the bone density and bone mass is reduced to such an extent that the bones and cartilages become more prone to cracks and fractures. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Osteoporosis Drugs Report by Material, Application, and Geography – Global Forecast to 2025 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). In this report, the global Osteoporosis Drugs market is valued at USD XX million in 2021 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2021 to 2025. The report firstly introduced the Osteoporosis Drugs basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it...

$3,200.00

Osteoporosis - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), r...

$2,000.00

Post Menopausal Osteoporosis - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descri...

$2,000.00

Osteoporosis - Pipeline Review, H2 2018

Thu, 29 Nov 2018 15:00:25 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), r...

$2,000.00

Post Menopausal Osteoporosis - Pipeline Review, H2 2018

Thu, 29 Nov 2018 13:32:16 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2018, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descri...

$2,000.00

Osteoporosis Drugs Markets in China

Wed, 09 May 2018 11:25:43 +0000

China's demand for Osteoporosis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2007, 2012 and 2017) and long-term forecasts through 2022 and 2027 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are co...

$4,000.00

Osteoporosis Drugs Industry Forecasts - China Focus

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Osteoporosis Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovat...

$1,800.00

Osteoporosis Drugs Companies in China

Wed, 09 May 2018 11:25:43 +0000

This study focuses on China’s Osteoporosis Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is sufferi...

$1,800.00

Post Menopausal Osteoporosis - Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 5-10 business days to complete. DelveInsight’s Post Menopausal Osteoporosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Post Menopausal Osteoporosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Post Menopausal Osteoporosis till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Post Menopausal Osteoporosis market. • Identifying patient populations in the global “Post Menopausal Osteoporosismarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Post Meno...

$4,950.00

Epiomic Epidemiology Series: Osteopenia & Osteoporosis Forecast in 13 Major Markets 2017-2027

Thu, 09 Mar 2017 15:20:59 +0000

Osteopenia and osteoporosis (“porous bone”) are both terms which help to define the continuum of loss of bone density which leads to bone fragility and an increased risk of fractures of the hip, spine and wrist. Loss of bone density is characterised by too little bone formation, excessive bone loss or a combination of both, typically as a result of hormonal changes, or deficiency of calcium or vitamin D. Both osteopenia and osteoporosis remain largely under diagnosed because of their asymptomatic nature, especially in the less severe stages of bone loss. This report provides the current prevalent population for Osteopenia and Osteoporosis across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Russia and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from our analysis team, several of the ma...

$6,400.00

Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast

Mon, 24 Oct 2016 11:23:19 +0000

Renub Research report titled “Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast” provides a comprehensive analysis of the current state of the market and likely future evolution over the next 5 years. This 21 page report with 12 Figures provides a sales analysis of covered companies. Worldwide Osteoporosis – Company Wise Drugs Sales Analysis (2010 – 2019) 1) Merck 2) Sanofi 3) Novartis 4) Eli Lilly 5) Amgen Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephonic interviews with industry experts. Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 pa...

$350.00

Osteoporosis - Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

DelveInsight’s Osteoporosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Osteoporosis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Osteoporosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Osteoporosis till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Osteoporosis market. • Identifying patient populations in the global “Osteoporosis market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Osteoporosis therapeutics in each of the markets covered. • To understand the future market competition in the global Osteoporosis therapeutics market a...

$4,950.00

Osteoporosis - Pipeline Review, H1 2016

Tue, 07 Jun 2016 19:33:56 +0000

Summary

Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2016’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations a...

$2,000.00

Post Menopausal Osteoporosis - Pipeline Review, H1 2016

Tue, 31 May 2016 09:45:03 +0000

Summary

Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2016’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical tria...

$2,000.00